Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease

[hotblack]

I first heard about this in a paywalled reuters article

Bayer's (BAYGn.DE), opens new tab pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's long-term growth projects.
Rivals in cell and gene therapy technologies are already generating revenue from treating cancer or rare hereditary diseases, but Bayer is entering new territory through subsidiary BlueRock's bemdaneprocel, an experimental Parkinson's disease treatment designed to replace dopamine-producing brain cells killed by the disease.

More info in this press release from a few days ago

BERLIN, September 22, 2025--(BUSINESS WIRE)--Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II clinical trial of AB-1005, an investigational gene therapy. Both therapies are focused on treating moderate-stage PD and are being developed in collaboration with Bayer’s wholly owned, independently operated subsidiary companies, BlueRock Therapeutics LP (bemdaneprocel) and AskBio Inc. (AB-1005) respectively.

Source - Yahoo Finance

There’s also a nature article from earlier in he year but it’s also paywalled.

And some older items from the company website on this technology.
Bayer - Cell and Gene Therapy
Charting a New Course for Parkinson’s Disease

 

[hotblack]

Here’s the paper on the phase 1 trial of Bemdaneprocel
https://www.nature.com/articles/s41586-025-08845-y
And a paper on a phase 1 and 2 trial it seems
https://www.nature.com/articles/s41586-025-08700-0
Finally info on the phase 3 trial exPDite-2
https://clinicaltrials.gov/study/NCT06944522

Here’s the paper on the phase 1 trial of AB-1005
https://www.neurology.org/doi/abs/10.1212/WNL.0000000000206690
And info on the phase 2 trial REGENERATE-PD
https://clinicaltrials.gov/study/NCT06285643
https://www.askbio.com/genetic-disease-focus/parkinsons-disease/#regenerate-pd